Perspective Therapeutics plans May 2026 analyst event, Q1 results, and conference appearances. The radiopharmaceutical firm is advancing 212Pb-based therapies in Phase 1/2a trials and expanding facilities.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
China's pharma industry hit record clinical drug trials and out-licensing deal values in 2025 and H1 2026, with NMPA approvals surging. The growth has drawn US Senate scrutiny and new bipartisan oversight legislation.
NEOK Bio dosed first patients in Phase 1 trials of lead bispecific ADCs NEOK001 and NEOK002 for advanced solid tumors. The candidates target B7-H3/ROR1 and EGFR/MUC1, with initial data expected in 2027.
FDA approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion-positive cholangiocarcinoma on May 8, 2026. The eNRGy trial showed a 36.8% ORR. It also received priority review, breakthrough, and orphan designations.
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
Sponsors are adopting AI-enabled tools, integrated operating models and decentralized designs to accelerate clinical trials. FDA and EMA guidance underscores sponsor accountability, while new modeling links integrated operations to higher program value.
China has approved the world's first CAR-T cell therapy for solid tumors, specifically for stomach cancer, developed by CARsgen Therapeutics. Meanwhile, the WVU Cancer Institute has conducted the first-ever use of a subcutaneous formulation of blinatumomab to achieve remission in a patient with ultra-rare mixed phenotype acute leukemia.
Sensei Biotherapeutics has changed its name to Faeth Therapeutics following its February 2026 acquisition of the biotechnology company. The name change accompanies a $200 million private placement financing to advance PIKTOR, an investigational all-oral multi-node inhibitor targeting the PI3K/AKT/mTOR pathway in endometrial and breast cancer. Topline Phase 2 data in endometrial cancer is anticipated in the second half of 2026.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780318 |
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07778862 |
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07769242 |
Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07769229 |
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors |
NOT_YET_RECRUITING | PHASE2 |
| NCT07763652 |
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07763639 |
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07727317 |
Evaluate the Diagnostic Efficacy and Safety of INR 202 PET/CT Imaging in Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | NA |
| NCT07689812 |
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. |
NOT_YET_RECRUITING | NA |
| NCT07661459 |
Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI) |
RECRUITING | PHASE2 |
| NCT07657611 |
Inhaled mRNA Immunotherapy for Patients With Advanced Lung Cancer or Pulmonary Metastatic Solid Tumors |
NOT_YET_RECRUITING | EARLY_PHASE1 |
